Photodynamic therapy in the treatment of cancer: Current state of the art

Drugs

Volumn 57, Issue 5, 1999, Pages 725-734

  Hsi, R Alex ^a   Rosenthal, David I ^a   Glatstein, Eli ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN; PHOTOSENSITIZING AGENT; SINGLET OXYGEN;

ABSORPTION; CANCER; CANCER CELL; CELL KILLING; DRUG PENETRATION; LIGHT; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; REVIEW; SKIN;

HUMANS; LIGHT; NEOPLASMS; OXYGEN CONSUMPTION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 0032923286     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957050-00005     Document Type: Review

References (71)

1. Lipson RL, Baldes EJ, Olsen EM. The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 1961; 26: 1
2. Dougherty TJ. Photosensitization of malignant tumors. Semin Surg Oncol 1986; 2: 24-37
3. Miller DS. The use of the laser in gynecology. J S C Med Assoc 1983; 79: 627-30
4. Wilson BC, Patterson MS. The physics of photodynamic therapy. Phys Med Biol 1986; 31: 327-60
5. Moan J, Berg K. The photodegredation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991; 53: 549-53
6. Moan J, Pettersen EO, Christensen T. The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin. Br J Cancer 1979; 39: 398-407
7. Volden G, Christensen T, Moan J. Photodynamic membrane damage of hematoporphyrin derivative-treated NHIK 3025 cells in vitro. Photobiochem Photobiophys 1981; 3: 105-11
8. 2+-ATPase in R3230AC rat mammary adenocarcinomas. Cancer Res 1988; 48: 3360-6
9. Russo A, DeGraff W, Kinsella TJ, et al. Potentiation of chemotherapy cytotoxicity following iododeoxyuridine incorporation in Chinese hamster cells. Int J Radiat Oncol Biol Phys 1986; 12: 1371-4
10. Gomer CJ, Rucker N, Banerjee A, et al. Comparison of mutagenicity and induction of sister chromatid exchange in Chinese hamster cells exposed to derivative, ionizing radiation, or ultraviolet radiation. Cancer Res 1983; 43: 2622-7
11. Moan J, Waksvik H, Christensen T. DNA single-stranded breaks and sister chromatid exchanges induced by treatment with hematoporphyrin and light or by x-rays in human NHIK 3025 cells. Cancer Res 1980; 40: 2915-8
12. Mitchell JB, Russo A, Kinsella TJ, et al. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 1513-8
13. Fingar VH, Siegel KA, Wieman TJ, et al. The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. Photochem Photobiol 1993; 58: 393-9
14. Fingar VH, Wieman TJ, Haydon PS. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using Photofrin. Photochem Photobiol 1997; 66: 513-7
15. Fingar VH, Wieman TJ, Karavolos PS, et al. The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response. Photochem Photobiol 1993; 58: 251-8
16. McMahon KS, Wieman TJ, Moore PH, et al. Effects of photodynamic therapy using mono-L-aspartyl chlorin c6 on vessel constriction, vessel leakage, and tumor response. Cancer Res 1994; 54: 5374-9
17. Gilissen MJ, van de Merbel-de Wit LE, Star WM, et al. Effect of photodynamic therapy on the endothelium-dependent relaxation of isolated rat aortas. Cancer Res 1993; 53: 2548-52
18. Korbelik M. The role of nitric oxide in the response of solid tumors to photodynamic therapy [abstract]. Photochem Photobiol 1997; 65: 55S-6S
19. Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J Photochem Photobiol B 1998; 42: 89-95
20. Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147-57
21. Kluck RM, Martin SJ, Hoffman BM, et al. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a xenopus cell-free apoptosis system. EMBO J 1997; 16: 4639-49
22. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996; 14: 329-34
23. Allison BA, Pritchard PH, Levy JG. Evidence for low density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994; 69: 833-9
24. Maziere JC, Morliere P, Santus R. The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumors. J Photochem Photobiol B 1991; 8: 351-60
25. Soncin M, Polo L, Reddi E, et al. Effect of axial ligation and delivery system on the tumor-localising and -photosensitizing properties of Ge(IV)-octabutoxy-phthalocyanines. Br J Cancer 1995; 71: 727-32
26. Korbelik M. Low density lipoprotein receptor pathway in the delivery of photofrin: how much is it relevant for selective accumulation of the photosensitizer in tumors? J Photochem Photobiol B 1992; 12: 107-19
27. Kessel D. HPD: structure determinants of localization. In: Kessel D, editor. Photodynamic therapy of neoplastic diseases. Boca Raton (FL); CRC Press, 1990: 1-14
28. Berg K, Anholt H, Moan J, et al. Photobiological properties of haematoporphyrin diesters: evaluation of possible applications in photochemotherapy. J Photochem Photobiol B 1995; 20: 37-45
29. Jori G. Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. J Photochem Photobiol B 1996; 36: 87-93
30. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996; 56: 1194-8
31. Barrett AJ, Kennedy JC, Jones RA, et al. The effect of tissue and cellular pH on the selective biodistribution of porphyrin-type photochemotherapeutic agents: a volumetric titration study. J Photochem Photobiol B 1990; 6: 309-23
32. Pottier R, Kennedy JC. The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J Photochem Photobiol B 1990; 8: 1-16
33. Mew D, Wat CK, Towers GHN, et al. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-porphyrin conjugates. J Immuol 1993; 130: 1473-7
34. Hasan T. Photosensitizer delivery mediated by macromolecular carrier systems. In: Henderson BW, Dougherty TJ, editors. Photodynamic therapy: basic principles and clinical applications. New York: Marcel-Dekker, 1992: 187-200
35. Foster TH, Murant RS, Bryant RG, et al. Oxygen consumption and diffusion effects in therapy. Radiat Res 1991; 126: 296-303
36. Sitnik TM, Henderson BW. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol 1998; 67: 462-6
37. Van Geel IPJ, Oppelaar H, Marijnissen JPA, et al. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. Radiat Res 1996; 145: 602-9
38. Gibson SL, VanDerMeid KR, Murant RS, et al. Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas. Cancer Res 1990; 50: 7236-41
39. Bellnier DA, Lin CW. Photosensitization and split-dose recovery in cultured human urinary bladder carcinoma cells containing nonexchangeable hematoporphyrin derivative. Cancer Res 1985; 45: 2507-11
40. Bays R, Wagnieres G, Robert D, et al. Light dosimetry for photodynamic therapy in the esophagus. Lasers Surg Med 1997; 20: 290-303
41. Friauf WS, Smith PE, Russo A, et al. Light monitoring in photodynamic therapy. In: Nagle HT, Tomkins WJ, editors. IEEE case studies in medical instrument design. New York: IEEE, 1992: 127-38
42. Baas P, Murrer L, Zoetmulder FAN, et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997; 76: 819-26
43. Fenning MC, Brown DQ, Chapman JD. Photodosimetry of interstitial light delivery to solid tumors. Med Phys 1994; 21: 1149-56
44. 3H BPD-MA): a new potent photosensitizer in normal and tumor-bearing mice. J Photochem Photobiol B 1990; 5: 231-44
45. Levy J. The preclinical and clinical development of Photofrin® and benzoporphyrin derivative: a reflection on opportunities and changes. J Photochem Photobiol B 1995; 30: 79-82
46. Levy J, Chan A, Strong HA. The clinical status of benzoporphyrin derivative. Proc Int Soc Optical Engineering 1995; 2625: 86-95
47. Van Geel IPG, Oppelaar H, Oussoren YG, et al. Photosensitizing efficacy of mTHPC-PDT compared to Photofrin-PDT in the RIF-1 mouse tumour and normal skin. Int J Cancer 1995; 60: 388-94
48. Ronn AM, Lofgren LA, Westborn KM. Interspecies pharmacokinetics as applied to the "hard drug" photosensitizing agent meta (tetrahydroxylchlorin). Proc Int Soc Optical Engineering 1995; 2625: 118-23
49. Tralau CJ, Barr H, Sanderman R, et al. Aluminum sulfonated phthalocyanine distribution in rodent tumors of the colon, brain and pancreas. Photochem Photobiol 1987; 46: 777-81
50. Young SW, Qing F, Harriman A, et al. Gadolinium (III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 1996; 93: 6610-5
51. Yuen AR, Panella TJ, Wieman J, et al. Phase I trial of photodynamic therapy with lutetium lexaphyrin (LU-TEX) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 219a
52. Regula J, MacRobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolacvulinic acid induced protoporphyrin IX: a pilot study. Gut 1995; 36: 67-75
53. Peng Q, Berg K, Moan J, et al. 5-aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 1997; 65: 235-51
54. DeLancy TF, Sindelar WF, Tochner Z, et al. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993; 25: 445-57
55. Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer: a multicenter trial. Gastrointest Endosc 1995; 42: 507-12
56. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am 1997; 2: 207-20
57. Moghissi K, Dixon K, Parsons RJ. A controlled trial of Nd-YAG laser vs photodynamic therapy for advanced malignant bronchial obstruction. Lasers Med Sci 1993; 8: 269-73
58. Cortese DA, Edell ES, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 1997; 72: 595-602
59. Pass HI, DeLaney TF, Tochner Z, et al. Intrapleural photodynamic therapy: results of a phase I trial. Ann Surg Oncol 1994; 1: 28-37
60. Benson RC. Laser photodynamic therapy for bladder cancer. Mayo Clin Proc 1986; 61: 859-64
61. Prout GR, Lin CW, Benson RC, et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med 1987; 317: 1251-5
62. Tsuchiya A, Obara N, Miwa M, et al. Hematoporphyrin derivative and laser photoradiation in the diagnosis and treatment of bladder cancer. J Urol 1983; 130: 79-82
63. Hisazumi H, Misaki T, Miyoshi N. Photoradiation therapy of bladder tumors. J Urol 1983; 130: 685-7
64. Chang SC, Buonaccorsi G, MacRobert A, et al. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int J Cancer 1996; 67: 555-62
65. Wilson BD, Mang TS, Stoll H, et al. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 1992; 128: 1597-601
66. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992; 6: 275-92
67. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. J Am Acad Dermatol 1993; 28: 17-21
68. Cairnduff F, Stringer MR, Hudson EJ, et al. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994; 69: 605-8
69. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical δ-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-51
70. Sperduto PW, DeLancy TF, Thomas G, et al. Photodynamic therapy for chest wall recurrence in breast cancer. Int J Radiat Oncol Biol Phys 1991; 21: 441-6
71. Gluckman JL. Hematoporphyrin photodynamic therapy: is there truly a future in head and neck oncology? Reflections on a 5-year experience. Laryngoscope 1991; 101: 36-42